Ono Pharmaceutical

4528 · TSE · Japan

Public Market Listing

4528TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Ono Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(16 total)
16Total Assets
11Approved
1Phase 3 / Filed
4Phase 1–2 / Early
18Diseases
Quick filter:
Showing 16 of 16 assets
Target & Modality
Approved
MEK1/2Small molecule
Non-Small Cell Lung CancerMelanoma
Approved
ProteasomeSmall molecule
Multiple Myeloma
Cenobamate(Xcopri)
Approved
Sodium channels + GABA-A receptorsSmall molecule
Epilepsy
Focal Onset Seizures
Dapagliflozin(Farxiga / Forxiga)
Approved
SGLT2Small molecule
Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease
Approved
BRAF V600ESmall molecule
Non-Small Cell Lung CancerColorectal CancerMelanoma
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Etelcalcetide(Parsabiv)
Approved
Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPeptide
Chronic Kidney Disease
Secondary Hyperparathyroidism
Approved
CTLA-4 antagonistMonoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEsophageal Cancer
Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Cutaneous Melanoma, Advanced Metastatic Colorectal Cancer
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerGastric CancerHead and Neck Squamous Cell CarcinomaBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEsophageal Cancer
Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Advanced Metastatic Colorectal Cancer
Opicapone(Ongentys)
Approved
COMTSmall molecule
Parkinson's Disease
Approved
LAG-3Monoclonal antibody
Non-Small Cell Lung CancerMelanoma
Sitagliptin(Januvia)
Approved
DPP-4Small molecule
Type 2 Diabetes
Phase 3
Prostaglandin E2 receptor 4 (EP4)Small molecule
Non-Small Cell Lung CancerGastric Cancer
Phase 2
Endocannabinoid synthesisSmall molecule
Fibromyalgia
Phase 2
Epigenetic regulation (target undisclosed)Small molecule
Alzheimer's Disease
Phase 1
Undisclosed / early pipelineSmall molecule
Chronic Kidney Disease

Upcoming events

(30 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Dapagliflozin · Farxiga / ForxigaPhase 2Chronic Kidney Disease and Hypertension
Est. primary completion 2026-12-10 · NCT07222917 · CT.gov ↗
What to watch
ONO-2020Phase 2Agitation Associated With Alzheimer's Disease Dementia
Est. primary completion 2026-12-31 · NCT06803823 · CT.gov ↗
What to watch
2027 (9)
January 2027 (2)
Cenobamate · XcopriPhase 2Epilepsies, Partial
Est. primary completion 2027-01-31 · NCT06590896 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3Epilepsy, Generalized
Est. primary completion 2027-01-31 · NCT06579573 · CT.gov ↗
What to watch
February 2027 (1)
Nivolumab + IpilimumabPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-02-05 · NCT06946797 · CT.gov ↗
What to watch
March 2027 (2)
Nivolumab + IpilimumabPhase 3Renal Cell Carcinoma
Est. primary completion 2027-03-11 · NCT03873402 · CT.gov ↗
What to watch
Binimetinib + EncorafenibPhase 3Melanoma
Est. primary completion 2027-03-31 · NCT05270044 · CT.gov ↗
What to watch
April 2027 (1)
Dapagliflozin · Farxiga / ForxigaPhase 3Heart Failure and Impaired Kidney Function
Est. primary completion 2027-04-16 · NCT06307652 · CT.gov ↗
What to watch
June 2027 (1)
Etelcalcetide · ParsabivPhase 3Secondary Hyperparathyroidism
Est. primary completion 2027-06-30 · NCT03969329 · CT.gov ↗
What to watch
August 2027 (1)
NivolumabPhase 3Extensive-Stage Small Cell Lung Cancer
Est. primary completion 2027-08-17 · NCT06646276 · CT.gov ↗
What to watch
December 2027 (1)
Nivolumab + IpilimumabPhase 2Pan-tumor
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
2028 (5)
February 2028 (2)
Nivolumab + ONO-4578Phase 2Colorectal Cancer
Est. primary completion 2028-02-15 · NCT06948448 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3Chronic Kidney Disease and Hypertension
Est. primary completion 2028-02-24 · NCT06268873 · CT.gov ↗
What to watch
March 2028 (1)
Cenobamate · XcopriPhase 3Partial Epilepsy
Est. primary completion 2028-03-30 · NCT07594158 · CT.gov ↗
What to watch
July 2028 (1)
Dapagliflozin · Farxiga / ForxigaPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-07-14 · NCT07662044 · CT.gov ↗
What to watch
August 2028 (1)
NivolumabPhase 2Solid Tumors
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
2029 (9)
January 2029 (3)
NivolumabPhase 1/2Advanced Solid Tumors
Est. primary completion 2029-01-04 · NCT06697197 · CT.gov ↗
What to watch
NivolumabPhase 2Rhabdoid Tumor
Est. primary completion 2029-01-31 · NCT06622941 · CT.gov ↗
What to watch
Etelcalcetide · ParsabivPhase 3Secondary Hyperparathyroidism, Chronic Kidney Disease
Est. primary completion 2029-01-31 · NCT03633708 · CT.gov ↗
What to watch
July 2029 (1)
NivolumabPhase 2Richter's Transformation
Est. primary completion 2029-07-31 · NCT06936943 · CT.gov ↗
What to watch
August 2029 (1)
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
October 2029 (1)
IpilimumabPhase 1/2Hepatocellular Carcinoma (HCC)
Est. primary completion 2029-10-15 · NCT07291076 · CT.gov ↗
What to watch
November 2029 (1)
IpilimumabPhase 1/2Advanced Renal Cell Carcinoma (RCC)
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
December 2029 (2)
Est. primary completion 2029-12-17 · NCT06677060 · CT.gov ↗
What to watch
Dapagliflozin · Farxiga / ForxigaPhase 3Chronic Kidney Disease and Hypertension
Est. primary completion 2029-12-18 · NCT06742723 · CT.gov ↗
What to watch
2030 (2)
July 2030 (2)
Dapagliflozin · Farxiga / ForxigaPhase 3Renal Insufficiency, Chronic
Est. primary completion 2030-07-01 · NCT07624305 · CT.gov ↗
What to watch
Nivolumab + RelatlimabPhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-07-30 · NCT06561386 · CT.gov ↗
What to watch
2031 (3)
January 2031 (1)
ONO-4578Phase 3Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma
Est. primary completion 2031-01 · NCT07818070 · CT.gov ↗
What to watch
February 2031 (1)
NivolumabPhase 1/2Lung Cancer, Breast Cancer
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
August 2031 (1)
NivolumabPhase 1/2Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer …
Est. primary completion 2031-08-31 · NCT04895709 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

31 January 2027FDA action dateCenobamatePDUFA date set for cenobamate oral suspension
US, FDA · Source ↗

Recent

4 November 2026Filing submittedCenobamateSK Biopharmaceuticals submits sNDA for cenobamate in PGTC seizures and pediatric focal-onset seizures
US, FDA · SK Biopharmaceuticals · Source ↗
29 October 2026Topline resultONO-1110Ono reports Phase 2 results of ONO-1110: the PHN, fibromyalgia and HIC studies missed their primary endpoints
Ono Pharmaceutical · Source ↗
15 June 2026Filing acceptedCenobamateFDA accepts NDA for cenobamate oral suspension
US, FDA · Source ↗
7 April 2026ApprovalDapagliflozinFDA approves Lupin's generic Dapagliflozin Tablets
US, FDA · Source ↗
13 February 2025Topline resultRelatlimabPhase 3 RELATIVITY-098 (NCT05002569) did not meet its primary endpoint of recurrence-free survival
Bristol Myers Squibb · Source ↗
20 March 2024Topline resultNivolumabCheckMate -9DW (NCT04039607) Phase 3 met its primary endpoint
Bristol Myers Squibb · Source ↗

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$3.4B$969M$1.5B—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.2B$985M$1.4B—report ↗
2024-FY$3.5B$772M$1.1B—report ↗
2023-FY$3.3B$701M$722M—report ↗
2022-FY$3.2B$674M$566M—report ↗